Senior Associate Scientist – Plate-Based Analytical Assays – Transitional and Early Development

with 4+ years, or M.S.

with 2+ years of relevant biopharmaceutical industry experience focusing on assay development and/or early research screening.

Extensive, hands-on expertise in developing, optimizing, and troubleshooting ligand-binding assays (especially ELISAs).

Demonstrated ability to design and evaluate tool reagents for novel assay development.

Direct experience with biophysical/colloidal stability screening assays such as AC-SINS and PEG precipitation assays.

Understanding of the analytical requirements for transitioning early research assays into validate-able methods for late-stage Analytical Development and Quality Control.

Senior Associate Scientist in the Transitional and Early Development team, you will play a critical role in bridging early discovery and clinical development for Elanco’s biotherapeutics pipeline.

This laboratory-based position focuses on the design, execution, and optimization of research-stage plate-based analytical assays to support the screening and characterization of hit monoclonal antibodies (mAbs) and other complex biomolecules.

You will be responsible for building customized screening assays (including receptor blocking ELISAs, AC-SINS, and PEG assays) and designing the necessary tool reagents to evaluate early-stage molecules.

Furthermore, you will develop robust quantitative ELISAs for lead molecules, ensuring these methods are phase-appropriate and ready for seamless tech transfer to Analytical Development once projects approach Pipeline Entry.

Perform routine and customized research-stage plate assays, including receptor blocking ELISAs, quantitative ELISAs, AC-SINS, and PEG precipitation assays to screen hit mAbs and other biomolecules.

Develop, optimize, and qualify quantitative ELISAs for lead candidate molecules.